| Autor: |
van der Aa, D. C., Gisbertz, S. S., Anderegg, M. C. J., Lagarde, S. M., Klaassen, R., Meijer, S. L., van Dieren, S., Hulshof, Mccm, Bergman, Jjghm, Bennink, R. J., van Laarhoven, H. W. M., van Berge Henegouwen, M. I. |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Zdroj: |
van der Aa, D C, Gisbertz, S S, Anderegg, M C J, Lagarde, S M, Klaassen, R, Meijer, S L, van Dieren, S, Hulshof, M, Bergman, J, Bennink, R J, van Laarhoven, H W M & van Berge Henegouwen, M I 2023, ' 18F-FDG-PET/CT to Detect Pathological Complete Response After Neoadjuvant Treatment in Patients with Cancer of the Esophagus or Gastroesophageal Junction : Accuracy and Long-Term Implications ', Journal of gastrointestinal cancer . https://doi.org/10.1007/s12029-023-00951-2 |
| DOI: |
10.1007/s12029-023-00951-2 |
| Popis: |
Purpose : The curative strategy for patients with esophageal cancer without distant metastases consists of esophagectomy with preceding chemo(radio)therapy (CRT). In 10–40% of patients treated with CRT, no viable tumor is detectable in the resection specimen (pathological complete response (pCR)). This study aims to define the clinical outcomes of patients with a pCR and to assess the accuracy of post-CRT FDG-PET/CT in the detection of a pCR. Methods: Four hundred sixty-three patients with cancer of the esophagus or gastroesophageal junction who underwent esophageal resection after CRT between 1994 and 2013 were included. Patients were categorized as pathological complete responders or noncomplete responders. Standardized uptake value (SUV) ratios of 135 post-CRT FDG-PET/CTs were calculated and compared with the pathological findings in the corresponding resection specimens. Results: Of the 463 included patients, 85 (18.4%) patients had a pCR. During follow-up, 25 (29.4%) of these 85 patients developed recurrent disease. Both 5-year disease-free survival (5y-DFS) and 5-year overall survival (5y-OS) were significantly higher in complete responders compared to noncomplete responders (5y-DFS 69.6% vs. 44.2%; P = 0.001 and 5y-OS 66.5% vs. 43.7%; P = 0.001). Not pCR, but only pN0 was identified as an independent predictor of (disease-free) survival. Conclusion: Patients with a pCR have a higher probability of survival compared to noncomplete responders. One third of patients with a pCR do develop recurrent disease, and pCR can therefore not be equated with cure. FDG-PET/CT was inaccurate to predict pCR and therefore cannot be used as a sole diagnostic tool to predict pCR after CRT for esophageal cancer. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
